Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
Animals
Anti-Infective Agents
/ administration & dosage
Azithromycin
/ administration & dosage
Bronchi
/ cytology
Chlorocebus aethiops
Cricetinae
Disease Models, Animal
Drug Therapy, Combination
Female
Humans
Hydroxychloroquine
/ administration & dosage
Lung
/ pathology
Mesocricetus
Middle Aged
Plasma
/ virology
Real-Time Polymerase Chain Reaction
SARS-CoV-2
/ drug effects
Vero Cells
COVID-19 Drug Treatment
Antivirals
Azithromycin
COVID-19
Coronavirus
Ex vivo
Human airway epithelium
Hydroxychloroquine
In vivo
SARS-CoV-2
Syrian hamster
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
13
09
2021
revised:
16
11
2021
accepted:
22
11
2021
pubmed:
29
11
2021
medline:
19
1
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
Drug repositioning has been used extensively since the beginning of the COVID-19 pandemic in an attempt to identify antiviral molecules for use in human therapeutics. Hydroxychloroquine and azithromycin have shown inhibitory activity against SARS-CoV-2 replication in different cell lines. Based on such in vitro data and despite the weakness of preclinical assessment, many clinical trials were set up using these molecules. In the present study, we show that hydroxychloroquine and azithromycin alone or combined does not block SARS-CoV-2 replication in human bronchial airway epithelia. When tested in a Syrian hamster model, hydroxychloroquine and azithromycin administrated alone or combined displayed no significant effect on viral replication, clinical course of the disease and lung impairments, even at high doses. Hydroxychloroquine quantification in lung tissues confirmed strong exposure to the drug, above in vitro inhibitory concentrations. Overall, this study does not support the use of hydroxychloroquine and azithromycin as antiviral drugs for the treatment of SARS-CoV-2 infections.
Identifiants
pubmed: 34838583
pii: S0166-3542(21)00202-3
doi: 10.1016/j.antiviral.2021.105212
pmc: PMC8611861
pii:
doi:
Substances chimiques
Anti-Infective Agents
0
Hydroxychloroquine
4QWG6N8QKH
Azithromycin
83905-01-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105212Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Clin Kidney J. 2013 Oct;6(5):533-6
pubmed: 26120446
Eur Respir J. 2015 Feb;45(2):428-39
pubmed: 25359346
Vector Borne Zoonotic Dis. 2008 Dec;8(6):837-9
pubmed: 18620511
Sci Rep. 2016 Jun 28;6:28698
pubmed: 27350308
Int J Antimicrob Agents. 2019 Apr;53(4):362-369
pubmed: 30599241
Int J Antimicrob Agents. 2020 Aug;56(2):106020
pubmed: 32862840
Nat Commun. 2021 Mar 19;12(1):1735
pubmed: 33741945
Nature. 2020 Sep;585(7826):588-590
pubmed: 32698190
Respir Res. 2010 Jun 30;11:90
pubmed: 20591166
Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93
pubmed: 24841273
J Virol. 2020 Oct 14;94(21):
pubmed: 32817221
PLoS One. 2011 Feb 09;6(2):e16142
pubmed: 21347398
Am J Med. 1983 Jul 18;75(1A):5-10
pubmed: 6603166
Cell Rep. 2021 Apr 6;35(1):108959
pubmed: 33811811
Influenza Other Respir Viruses. 2007 Sep-Nov;1(5-6):189-92
pubmed: 19453426
Science. 2021 Jul 30;373(6554):541-547
pubmed: 34326236
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Viruses. 2021 Apr 09;13(4):
pubmed: 33918670
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
PLoS Pathog. 2021 Jan 19;17(1):e1009212
pubmed: 33465165
Antivir Chem Chemother. 2006;17(5):275-84
pubmed: 17176632
Eur J Pharmacol. 1996 Oct 24;314(1-2):203-14
pubmed: 8957238
Antiviral Res. 2021 Sep;193:105137
pubmed: 34265358
Kidney Med. 2021 Mar 18;3(3):442-446
pubmed: 34136790
Toxicol Appl Pharmacol. 2007 Jan 1;218(1):72-8
pubmed: 17156806
PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785
pubmed: 20706626
Int J Antimicrob Agents. 2020 May;55(5):105960
pubmed: 32251731
Oncotarget. 2017 May 9;8(19):31601-31611
pubmed: 28415826
Ther Drug Monit. 2021 Aug 1;43(4):570-576
pubmed: 33165216
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
ACS Infect Dis. 2015 Jul 10;1(7):317-26
pubmed: 27622822
Biopharm Drug Dispos. 1991 Oct;12(7):505-14
pubmed: 1657238
J Infect Dis. 1955 Sep-Oct;97(2):146-51
pubmed: 13263642
Toxicol Appl Pharmacol. 1969 May;14(3):510-4
pubmed: 5787519
Cell Syst. 2019 Feb 27;8(2):97-108.e16
pubmed: 30797775
Biomed Res Int. 2013;2013:392010
pubmed: 24073402
Cell Res. 2013 Feb;23(2):300-2
pubmed: 23208422
Cell Rep Med. 2020 Jul 21;1(4):100059
pubmed: 32835306
Mol Genet Metab Rep. 2021 May 29;28:100773
pubmed: 34136356
Microb Pathog. 2020 Aug;145:104228
pubmed: 32344177
Antimicrob Agents Chemother. 1994 Apr;38(4):790-8
pubmed: 8031048
Ultrastruct Pathol. 2020 Nov 20;44(4-6):519-523
pubmed: 33274661
J Allergy Clin Immunol. 2018 Jun;141(6):2074-2084
pubmed: 28797733
Lancet Infect Dis. 2011 Sep;11(9):677-83
pubmed: 21550310
Emerg Infect Dis. 2015 Jun;21(6):1065-7
pubmed: 25988934
Clin Pharmacol Ther. 2020 Nov;108(5):976-984
pubmed: 32531808
Nature. 2020 Sep;585(7826):584-587
pubmed: 32698191
JCI Insight. 2020 Dec 3;5(23):
pubmed: 33090972
EBioMedicine. 2017 Oct;24:189-194
pubmed: 29033372
Pak J Pharm Sci. 2020 May;33(3):1079-1085
pubmed: 33191232
Ultrastruct Pathol. 2013 Apr;37(2):146-50
pubmed: 23573895
J Gen Virol. 2020 Nov;101(11):1156-1169
pubmed: 32821033
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965
pubmed: 33037151
Trends Microbiol. 2018 Oct;26(10):865-876
pubmed: 29759926
Int J Antimicrob Agents. 2021 Feb;57(2):106247
pubmed: 33259916
Sci Rep. 2020 Aug 4;10(1):13093
pubmed: 32753646
PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006848
pubmed: 30356305